Related Experiment Video
Updated: May 3, 2026

Imaging- and Flow Cytometry-based Analysis of Cell Position and the Cell Cycle in 3D Melanoma Spheroids
Published on: December 28, 2015
Spherical Manifolds Capture Drug-Induced Changes in Tumor Cell Cycle Behavior
Olivia Wen1, Samuel C Wolff2, Wayne Stallaert3
1Department of Biology, University of North Carolina at Chapel Hill, NC, United States.
Abstract:
CDK4/6 inhibitors such as palbociclib block cell cycle progression and improve outcomes for many ER+/HER2- breast cancer patients. Unfortunately, many patients are initially resistant to the drug or develop resistance over time in part due to heterogeneity among individual tumor cells. To better understand these mechanisms of resistance, we used multiplex, single-cell imaging to profile cell cycle proteins in ER+ breast tumor cells under increasing palbociclib concentrations. We then applied spherical principal component analysis (SPCA), a dimensionality reduction method that leverages the inherently cyclical nature of the high-dimensional imaging data, to look for changes in cell cycle behavior in resistant cells. SPCA characterizes data as a hypersphere and provides a framework for visualizing and quantifying differences in cell cycles across treatment-induced perturbations. The hypersphere representations revealed shifts in the mean cell state and population heterogeneity. SPCA validated expected trends of CDK4/6 inhibitor response such as decreased expression of proliferation markers (Ki67, pRB), but also revealed potential mechanisms of resistance including increased expression of cyclin D1 and CDK2. Understanding the molecular mechanisms that allow treated tumor cells to evade arrest is critical for identifying targets of future therapies. Ultimately, we seek to further SPCA as a tool of precision medicine, targeting treatments by individual tumors, and extending this computational framework to interpret other cyclical biological processes represented by high-dimensional data.
Insights
CDK4/6 inhibitors show promise in ER+/HER2- breast cancer, but resistance is common. New computational methods reveal cell cycle shifts and potential resistance mechanisms, aiding precision medicine development.
Area of Science:
- Oncology
- Computational Biology
- Cell Biology
Background:
- CDK4/6 inhibitors like palbociclib are effective against ER+/HER2- breast cancer.
- Tumor cell heterogeneity contributes to primary and acquired resistance to these therapies.
- Understanding resistance mechanisms is crucial for developing more effective treatments.
Purpose of the Study:
- To investigate cell cycle protein profiles in ER+ breast cancer cells under palbociclib treatment.
- To identify mechanisms of resistance to CDK4/6 inhibitors using advanced computational analysis.
- To explore the utility of spherical principal component analysis (SPCA) for interpreting high-dimensional biological data.
Main Methods:
- Multiplex single-cell imaging was employed to profile cell cycle proteins.
- Increasing concentrations of palbociclib were used to induce varying levels of drug response.
- Spherical principal component analysis (SPCA) was applied to analyze high-dimensional cell cycle data.
Main Results:
- SPCA visualized shifts in cell cycle states and population heterogeneity.
- The analysis confirmed expected reductions in proliferation markers (Ki67, pRB).
- Potential resistance mechanisms, including increased cyclin D1 and CDK2 expression, were identified.
Conclusions:
- SPCA is a valuable tool for analyzing cell cycle dynamics and identifying resistance mechanisms in cancer.
- Understanding these resistance pathways can inform the development of novel therapeutic strategies.
- SPCA holds potential as a precision medicine tool for tailoring cancer treatments.

